Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
NCT00003984 · European Organisation for Research and Treatment of Cancer - EORTC · PHASE2 · withdrawn · last registry update 2012-07-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, European Organisation for Research and Treatment of Cancer - EORTC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD33 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-03-08Results posted on the registry: M.D. Anderson Cancer Center, Decitabine + Gemtuzumab Ozogamicin (NCT00968071)
- 2013-02-12Results posted on the registry: Eastern Cooperative Oncology Group, sargramostim + busulfan (NCT00049517)
- 2012-08-27Results posted on the registry: SWOG Cancer Research Network, gemtuzumab ozogamicin + Cytosine arabinoside (NCT00085709)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision